|
1
|
Trapé AP and Gonzalez-Angulo AM: Breast
cancer and metastasis: on the way toward individualized therapy.
Cancer Genomics Proteomics. 9:297–310. 2012.PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Harbeck N: Never too late: reducing late
breast cancer relapse risk. Curr Med Res Opin. 24:3295–3305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Simstein R, Burow M, Parker A, Weldon C
and Beckman B: Apoptosis, chemoresistance, and breast cancer:
insights from the MCF-7 cell model system. Exp Biol Med.
228:995–1003. 2003.PubMed/NCBI
|
|
5
|
Payne KK and Manjili MH: Adaptive immune
responses associated with breast cancer relapse. Arch Immunol Ther
Exp. 60:345–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Joerger M and Thürlimann B: Chemotherapy
regimens in early breast cancer: major controversies and future
outlook. Expert Rev Anticancer Ther. 13:165–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Redden MH and Fuhrman GM: Neoadjuvant
chemotherapy in the treatment of breast cancer. Surg Clin North Am.
93:493–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fuksa L, Micuda S, Grim J, Ryska A and
Hornychova H: Predictive biomarkers in breast cancer: their value
in neoadjuvant chemotherapy. Cancer Invest. 30:663–678. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weiss RB: The anthracyclines: will we ever
find a better doxorubicin? Semin Oncol. 19:670–686. 1992.PubMed/NCBI
|
|
10
|
Prados J, Melguizo C, Ortiz R, et al:
Doxorubicin-loaded nanoparticles: new advances in breast cancer
therapy. Anticancer Agents Med Chem. 12:1058–1070. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brunello A, Roma A, Falci C and Basso U:
Chemotherapy and targeted agents for elderly women with advanced
breast cancer. Recent Pat Anticancer Drug Discov. 3:187–201. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alm El-Din MA, El-Badawy SA and Taghian
AG: Breast cancer after treatment of Hodgkin’s lymphoma: general
review. Int J Radiat Oncol Biol Phys. 72:1291–1297. 2008.
|
|
13
|
Khalil MY, Mapa M, Shin HJ and Shin DM:
Advances in the management of malignant mesothelioma. Curr Oncol
Rep. 5:334–341. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giai M, Biglia N and Sismondi P:
Chemoresistance in breast tumors. Eur J Gynaecol Oncol. 12:359–373.
1991.
|
|
15
|
Sakamoto T, Horiguchi H, Oguma E and
Kayama F: Effects of diverse dietary phytoestrogens on cell growth,
cell cycle and apoptosis in estrogen-receptor-positive breast
cancer cells. J Nutr Biochem. 21:856–864. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Lemos ML: Effects of soy phytoestrogens
genistein and daidzein on breast cancer growth. Ann Pharmacother.
35:1118–1121. 2001.PubMed/NCBI
|
|
17
|
Usui T: Pharmaceutical prospects of
phytoestrogens. Endocr J. 53:7–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sarkar FH, Adsule S, Padhye S, Kulkarni S
and Li Y: The role of genistein and synthetic derivatives of
isoflavone in cancer prevention and therapy. Mini Rev Med Chem.
6:401–407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ravindranath MH, Muthugounder S, Presser N
and Viswanathan S: Anticancer therapeutic potential of soy
isoflavone, genistein. Adv Exp Med Biol. 546:121–165. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanagasabai R, Krishnamurthy K, Druhan LJ
and Ilangovan G: Forced expression of heat shock protein 27 (Hsp27)
reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene
expression in adriamycin-resistant human breast cancer cells. J
Biol Chem. 286:33289–33300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu L, Zhou D, Jiang X, Song K, Li K and
Ding W: Loss of E-cadherin in multidrug resistant breast cancer
cell line MCF-7/ Adr: possible implication in the enhanced invasive
ability. Eur Rev Med Pharmacol Sci. 16:1271–1279. 2012.PubMed/NCBI
|
|
22
|
Zhang HC, Zhang F, Wu B, et al:
Identification of the interaction between P-glycoprotein and Anxa2
in multidrug-resistant human breast cancer cells. Cancer Biol Med.
9:99–104. 2012.PubMed/NCBI
|
|
23
|
Gampenrieder SP, Rinnerthaler G and Greil
R: Neoadjuvant chemotherapy and targeted therapy in breast cancer:
past, present, and future. J Oncol. 2013:7320472013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Steward WP and Brown K: Cancer
chemoprevention: a rapidly evolving field. Br J Cancer. 109:1–7.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bartlett J, Canney P, Campbell A, et al:
Selecting breast cancer patients for chemotherapy: the opening of
the UK OPTIMA trial. Clin Oncol. 25:109–116. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Loo TW and Clarke DM: Location of the
rhodamine-binding site in the human multidrug resistance
P-glycoprotein. J Biol Chem. 277:44332–44338. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ruefli AA, Tainton KM, Darcy PK, Smyth MJ
and Johnstone RW: P-glycoprotein inhibits caspase-8 activation but
not formation of the death inducing signal complex (disc) following
Fas ligation. Cell Death Differ. 9:1266–1272. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Menard S, Pupa SM, Campiglio M and
Tagliabue E: Biologic and therapeutic role of HER2 in cancer.
Oncogene. 22:6570–6578. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Banerjee S, Li Y, Wang Z and Sarkar FH:
Multi-targeted therapy of cancer by genistein. Cancer Lett.
269:226–242. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tarkowski M, Kokocinska M and Latocha M:
Genistein in chemoprevention and treatment. Pol Merkur Lekarski.
34:54–57. 2013.(In Polish).
|
|
31
|
Swami S, Krishnan AV, Peehl DM and Feldman
D: Genistein potentiates the growth inhibitory effects of
1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role
of the direct inhibition of CYP24 enzyme activity. Mol Cell
Endocrinol. 241:49–61. 2005. View Article : Google Scholar
|
|
32
|
Yu Z, Tang Y, Hu D and Li J: Inhibitory
effect of genistein on mouse colon cancer MC-26 cells involved
TGF-beta1/Smad pathway. Biochem Biophys Res Commun. 333:827–832.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pabona JM, Dave B, Su Y, et al: The
soybean peptide lunasin promotes apoptosis of mammary epithelial
cells via induction of tumor suppressor PTEN: similarities and
distinct actions from soy isoflavone genistein. Genes Nutr.
8:79–90. 2013. View Article : Google Scholar
|
|
34
|
Zhu H, Cheng H, Ren Y, Liu ZG, Zhang YF
and De Luo B: Synergistic inhibitory effects by the combination of
gefitinib and genistein on NSCLC with acquired drug-resistance in
vitro and in vivo. Mol Biol Rep. 39:4971–4979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tacar O, Sriamornsak P and Dass CR:
Doxorubicin: an update on anticancer molecular action, toxicity and
novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Y, Du F, Chen W, Yao M, Lv K and Fu P:
Knockdown of dual specificity phosphatase 4 enhances the
chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to
doxorubicin. Exp Cell Res. 319:3140–3149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi R, Peng H, Yuan X, et al:
Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant
MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein
inhibition and apoptosis augmentation. J Cell Biochem.
114:1890–1900. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Coussens L, Yang-Feng TL, Liao YC, et al:
Tyrosine kinase receptor with extensive homology to EGF receptor
shares chromosomal location with neu oncogene. Science.
230:1132–1139. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Harari D and Yarden Y: Molecular
mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene.
19:6102–6114. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Seo HS, Choi HS, Choi HS, et al:
Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting
nuclear factor-kappaB signaling in HER2-overexpressing breast
cancer cells. Anticancer Res. 31:3301–3313. 2011.PubMed/NCBI
|
|
41
|
Choi EJ and Kim GH: Antiproliferative
activity of daidzein and genistein may be related to ERα/c-erbB-2
expression in human breast cancer cells. Mol Med Rep. 7:781–784.
2013.PubMed/NCBI
|
|
42
|
Mai Z, Blackburn GL and Zhou JR: Genistein
sensitizes inhibitory effect of tamoxifen on the growth of estrogen
receptor-positive and HER2-overexpressing human breast cancer
cells. Mol Carcinog. 46:534–542. 2007. View
Article : Google Scholar : PubMed/NCBI
|
